BPIFA1 and neoplasm: Preclinical CAR-T cell therapy studies in lung cancer by targeting several potential targets, like erythropoietin-producing hepatocellular carcinoma A2 (EphA2), lung-specific X protein (LUNX), variant domain 6 of CD44 gene (CD44V6), melanoma-associated antigen (MAGE)-A1, exhibited significant suppression of tumor growth (65–68).